A beta-thalassemia genetic test examines the HBB gene for variants that reduce or stop production of beta-globin, one of the protein chains in adult hemoglobin. Testing may confirm beta-thalassemia in a person with anemia or abnormal hemoglobin studies, identify a carrier, clarify an inconclusive newborn or prenatal screen, and define a couple’s reproductive risk. HBB results must be interpreted with a complete blood count, iron studies, and hemoglobin analysis because small red blood cells can have several causes and different hemoglobin variants can interact. A single pathogenic HBB variant usually causes beta-thalassemia trait, which is often mild. Two clinically significant variants may cause transfusion-dependent or non-transfusion-dependent disease, but severity depends on how much beta-globin each variant allows, alpha-globin balance, fetal hemoglobin modifiers, and other factors. Partner testing is essential because an HBB carrier can have a child with beta-thalassemia or a combined disorder such as sickle beta-thalassemia.
- HBB testing identifies beta-zero, beta-plus, structural hemoglobin, promoter, splice, and other clinically relevant variants.
- Beta-thalassemia trait commonly causes lifelong microcytosis and mild anemia, not iron deficiency by itself.
- Hemoglobin A2 is often elevated in carriers, but iron deficiency and certain variants can blur the pattern.
- Two carriers of clinically significant HBB variants commonly have a 25% affected-pregnancy risk.
- A partner with sickle cell trait or another HBB variant can create a serious compound hemoglobin disorder.
- A negative molecular test reduces risk but may require follow-up if blood indices and family history remain strongly suggestive.
Table of Contents
- Beta-Globin and the Disease Spectrum
- Reasons to Order HBB Testing
- Blood Tests Before and Alongside Genetics
- HBB Variants and Test Methods
- How to Read HBB Results
- Carrier and Partner Risk
- Prenatal and Family Testing
- Next Steps and Pitfalls
Beta-Globin and the Disease Spectrum
Hemoglobin carries oxygen inside red blood cells. The main adult form, hemoglobin A, contains two alpha-globin and two beta-globin chains. HBB provides the instructions for beta-globin. When an HBB variant reduces beta-globin production, unmatched alpha chains damage developing red blood cells, causing ineffective red-cell production, hemolysis, and anemia.
Beta-thalassemia is not a single level of severity. The traditional terms include beta-thalassemia trait or minor, beta-thalassemia intermedia, and beta-thalassemia major. Current clinical language often separates transfusion-dependent beta-thalassemia from non-transfusion-dependent beta-thalassemia because transfusion needs better reflect management. Genotype contributes strongly, but it does not perfectly predict the course.
A beta-zero, or β0, allele produces essentially no beta-globin from that copy of HBB. A beta-plus, or β+, allele allows reduced production. A person with one pathogenic variant and one working copy usually has beta-thalassemia trait. A person with two severe variants may develop profound anemia in infancy and require regular transfusions. Combinations that retain more beta-globin may cause a milder but still clinically important form with variable anemia, enlarged spleen, bone changes, thrombosis, pulmonary hypertension, iron loading, or other complications.
Some HBB variants change the structure of beta-globin rather than simply lowering its production. Hemoglobin S, C, E, and other variants can interact with a beta-thalassemia allele. For example, hemoglobin S/beta-thalassemia is a form of sickle cell disease, not uncomplicated beta-thalassemia trait. Hemoglobin E/beta-thalassemia ranges from mild to transfusion-dependent. This is why partner testing must evaluate the broader HBB gene and hemoglobin pattern, not only “thalassemia mutations.”
Modifiers outside HBB matter. Additional alpha-globin gene deletions can reduce the alpha-chain excess and sometimes lessen beta-thalassemia severity. Variants that maintain higher fetal hemoglobin can also soften disease. Conversely, extra alpha-globin copies may worsen chain imbalance. A genetic report may mention these modifiers, but clinical monitoring remains necessary.
Beta-thalassemia occurs worldwide and is more frequent in people with ancestry from the Mediterranean, Middle East, South and Southeast Asia, Africa, and parts of the Americas. Ancestry is not a reliable exclusion tool. Migration and mixed heritage mean that hemoglobinopathy testing should be based on clinical and reproductive needs rather than appearance or surname.
Reasons to Order HBB Testing
HBB testing is used for both diagnosis and carrier assessment. Diagnostic testing may be appropriate for persistent microcytic anemia that is not explained by iron deficiency, elevated hemoglobin A2, an abnormal hemoglobin fraction, a positive newborn screen, unexplained hemolysis, splenomegaly, transfusion dependence, or a family history of thalassemia or another hemoglobinopathy.
Carrier testing may be offered before pregnancy, at the first prenatal visit, when a reproductive partner is known to carry an HBB variant, or when a relative has a confirmed familial variant. Universal hemoglobinopathy testing in reproductive care can identify people whose ancestry or family history would not have predicted risk. Screening can use hemoglobin analysis, molecular testing, or both.
Genetic testing is particularly useful when conventional studies are unclear. Examples include borderline hemoglobin A2, coexisting iron deficiency, recent transfusion, pregnancy-related shifts, a suspected silent or mild HBB variant, and a complex pattern involving hemoglobin E, S, C, or another structural variant. It can also distinguish beta-thalassemia from alpha-thalassemia when the red-cell indices overlap.
In an affected child or adult, identifying both HBB variants helps confirm the diagnosis and may support prognosis, family testing, and treatment planning. It can also establish the exact familial changes needed for prenatal diagnosis or PGT-M. A broad anemia panel may be appropriate if the phenotype could result from red-cell membrane, enzyme, iron, or congenital dyserythropoietic disorders.
Timing affects interpretation. Blood drawn soon after transfusion may contain donor red cells and distort hemoglobin electrophoresis or high-performance liquid chromatography. DNA testing from the patient’s white blood cells is generally less affected by red-cell transfusion, although stem-cell transplantation can complicate results because blood DNA may represent the donor. The clinician should tell the laboratory about transfusions and transplant history.
A diagnostic test should not be confused with treatment monitoring. HBB sequencing does not measure current hemoglobin, iron overload, organ function, or transfusion needs. Those require clinical assessment and laboratory or imaging studies. The gene result explains inherited cause; it does not replace ongoing hematology care.
Blood Tests Before and Alongside Genetics
Beta-thalassemia evaluation usually begins with a complete blood count. Carriers often have a low mean corpuscular volume, or MCV, and low mean corpuscular hemoglobin, or MCH. The red blood cell count may be normal or relatively high despite mild anemia. This differs from many cases of iron deficiency, but no single index is diagnostic.
Iron studies are essential. Ferritin, transferrin saturation, and the clinical context help determine whether iron deficiency is present. A person can have both iron deficiency and beta-thalassemia trait. Giving iron solely because the MCV is low can lead to unnecessary treatment, while assuming all microcytosis is thalassemia can miss treatable deficiency.
Hemoglobin analysis separates and measures hemoglobin fractions. Methods include high-performance liquid chromatography, capillary electrophoresis, and other electrophoretic techniques. In a typical adult beta-thalassemia carrier, hemoglobin A2 is elevated and hemoglobin F may be mildly increased. However, the pattern is not universal.
Several factors can mask or mimic beta-thalassemia trait:
- Iron deficiency may lower hemoglobin A2 in some people.
- Delta-globin variants or delta-thalassemia can reduce hemoglobin A2.
- Hemoglobin E may overlap with the A2 measurement on some platforms.
- Recent transfusion can introduce normal or variant donor hemoglobin.
- Pregnancy, age, and laboratory method can affect reference ranges.
- Mild promoter or “silent” HBB variants may cause nearly normal indices.
- Alpha-thalassemia can produce microcytosis without the typical A2 increase.
A blood smear may show small pale red cells, target cells, and variable shapes, but these findings are not specific. Reticulocyte count, bilirubin, lactate dehydrogenase, and haptoglobin help assess hemolysis. Severe disease may involve nucleated red cells and marked ineffective erythropoiesis.
Newborn interpretation differs because fetal hemoglobin dominates at birth and adult beta-globin production is still developing. A newborn screen can suggest absent or reduced hemoglobin A or identify a structural variant, but confirmatory testing is required. The exact timing and method depend on the screening pattern, symptoms, transfusion history, and local program.
Genetics and hematology are complementary. A convincing carrier pattern may be sufficient for some screening programs, while molecular confirmation is valuable when partner risk is present, the pattern is atypical, or prenatal testing is being considered. The strongest interpretation uses the DNA result and the person’s actual hemoglobin phenotype together.
HBB Variants and Test Methods
Most beta-thalassemia-causing variants are small sequence changes in or near HBB. They include splice-site changes, promoter variants, nonsense variants, frameshifts, and small insertions or deletions. Larger deletions involving HBB or the beta-globin gene cluster are less common but clinically important. The variant spectrum differs among populations, and hundreds of pathogenic variants have been described.
Targeted variant testing looks only for selected common or familial changes. It can be efficient when the exact family variant is known or in a population with a well-defined founder variant. Its limitation is obvious: a negative result does not exclude other HBB changes. For a partner of a known carrier, full-gene analysis is generally more informative than testing only for the first partner’s variant.
Sequence analysis detects most single-nucleotide variants and small insertions or deletions. Deletion and duplication analysis identifies larger copy-number changes that sequencing may miss. Some laboratories also assess regulatory regions, the beta-globin cluster, or known structural hemoglobin variants. A comprehensive test should state which regions and variant types are covered.
Next-generation sequencing panels often include HBB with HBA1, HBA2, and other red-cell genes. This is useful when alpha- and beta-thalassemia, unstable hemoglobin, or another inherited anemia are possible. However, homologous globin genes can be technically challenging, so laboratory validation matters more than panel size.
A known familial variant can be tested by Sanger sequencing, allele-specific analysis, gap-PCR for a deletion, or another focused method. Prenatal and preimplantation laboratories may request fresh confirmation of both parental variants before developing an assay. They may also use linked markers to reduce the chance of allele dropout or sample error.
The specimen is usually blood, saliva, or a cheek swab. No fasting is required. Blood provides both DNA and the option to perform hematologic studies, though the genetic and hemoglobin tests may be ordered separately. Turnaround time ranges from several days for targeted testing to several weeks for broader analysis.
A negative result should be checked against the assay’s limitations. Some deep regulatory variants, complex rearrangements, low-level mosaic changes, or variants in other genes may not be detected. If the blood pattern strongly supports beta-thalassemia, the laboratory may recommend expanded deletion analysis, family studies, or testing through a specialized hemoglobinopathy laboratory.
How to Read HBB Results
The report should identify the HBB variant in standardized DNA and protein notation, classify it, and describe the expected effect on beta-globin production. Some reports also use β0, β+, β++, or “silent” terminology. These labels are helpful, but the same variant can produce different severity in different genetic backgrounds.
| Result | Typical interpretation | What it does not prove |
|---|---|---|
| One pathogenic or likely pathogenic beta-thalassemia variant | Beta-thalassemia carrier/trait in most people | That the person has severe thalassemia |
| Two pathogenic variants on opposite HBB copies | Beta-thalassemia or a compound HBB disorder | Exact future severity without clinical correlation |
| One beta-thalassemia variant plus HbS, HbE, HbC, or another structural variant | Compound hemoglobinopathy | That the condition behaves like simple carrier status |
| Variant of uncertain significance | Evidence is insufficient | Carrier status or disease by itself |
| No pathogenic variant found | HBB cause not detected by the assay | Complete exclusion of thalassemia or another hemoglobin disorder |
A pathogenic or likely pathogenic result has enough evidence to be used clinically. One such variant, combined with typical microcytosis and elevated hemoglobin A2, supports beta-thalassemia trait. The person is usually healthy or mildly anemic but should avoid being mislabeled as iron deficient without iron studies.
Two variants must be evaluated for phase. “In trans” means one variant is on each HBB copy, which can cause disease. “In cis” means both are on the same chromosome, leaving the other HBB copy unaffected. Parental testing or other family studies may establish phase. In a person with a clear severe phenotype, trans configuration may be strongly supported even before family testing.
The predicted output from each allele matters. Two β0 variants usually cause severe loss of beta-globin. A β+ variant paired with another mild variant may produce non-transfusion-dependent disease. Hemoglobin E behaves as both a structural variant and a mild beta-plus allele, creating a particularly wide range when paired with beta-thalassemia.
A VUS should not be treated as a confirmed carrier or disease result. Evidence may come from hemoglobin studies, family segregation, RNA analysis, functional data, population frequency, and prior cases. The principles for interpreting uncertain findings are reviewed in a genetic variant results guide.
Reports can change. A variant may be reclassified as new evidence appears, and genotype–phenotype knowledge may improve. Reanalysis is appropriate when a VUS remains central to care, the clinical findings do not match the report, or the result was generated many years ago with limited methods.
Carrier and Partner Risk
Beta-thalassemia is usually autosomal recessive. If both reproductive partners carry clinically significant HBB variants, each pregnancy generally has a 25% chance of inheriting both variants, a 50% chance of inheriting one, and a 25% chance of inheriting neither. These probabilities reset for every pregnancy.
Partner testing must look beyond beta-thalassemia trait. A partner may carry hemoglobin S, E, C, D, or another HBB variant. Depending on the combination, a child could have sickle beta-thalassemia, hemoglobin E/beta-thalassemia, or another clinically significant compound disorder. Hemoglobin analysis plus molecular testing can define the pair more accurately than a limited mutation panel.
When one person is a confirmed carrier and the partner tests negative, reproductive risk falls but does not become zero. Residual risk depends on the partner’s pretest carrier probability, the sensitivity of hemoglobin and molecular testing, and whether uncommon deletions or regulatory variants were assessed. A normal CBC alone is not always sufficient because silent HBB alleles exist.
If the partner has microcytosis but normal hemoglobin A2, alpha-thalassemia and iron deficiency should be considered. This distinction changes reproductive counseling. Alpha- and beta-globin findings can interact in an affected child, but carriers of variants in different unrelated genes do not automatically have the same 25% beta-thalassemia risk.
A person with beta-thalassemia disease rather than trait passes one disease-causing HBB variant to every child if both HBB copies are affected. If the partner is a carrier, each pregnancy may have a 50% chance of an affected child and a 50% chance of a carrier child, depending on the exact genotypes. Personalized counseling is needed for structural variants and complex alleles.
Relatives may also be carriers. Full siblings of a carrier often have a 50% chance of carrying the same familial variant if one parent is heterozygous, though their own reproductive risk depends on their partner. Sharing the laboratory report is more useful than sharing only “thalassemia runs in the family.”
Carrier status can prevent repeated diagnostic confusion. A person with trait should tell clinicians about the result, especially during pregnancy or anemia evaluation. Iron should be used only when deficiency is demonstrated. Trait usually does not progress into transfusion-dependent thalassemia.
Prenatal and Family Testing
When both partners form an at-risk pair, genetic counseling should review the expected disease range and available options. The exact variants should be confirmed before pregnancy whenever possible because assay development and variant clarification take time.
Prenatal diagnosis can test fetal DNA obtained by chorionic villus sampling or amniocentesis. The laboratory looks for the known parental variants and may use linked markers to confirm inheritance and reduce technical error. These are diagnostic procedures; routine cell-free DNA screening does not provide the same definitive HBB result. Procedure timing and risks should be discussed with an obstetric specialist.
IVF with preimplantation genetic testing for monogenic disease can identify embryos that inherited zero, one, or two familial variants before transfer. PGT-M requires a customized test, IVF, and sufficient embryos for analysis. It does not guarantee pregnancy, and prenatal confirmation may still be offered. Donor eggs, donor sperm, donor embryos, adoption, natural conception without testing, and preparation for an affected child are also valid choices.
Testing an affected relative can resolve uncertainty in a family. If a deceased or unavailable relative was said to have “Mediterranean anemia,” old records may distinguish beta-thalassemia from alpha-thalassemia, sickle cell disease, or another anemia. A transfusion history, hemoglobin pattern, and genetic report are especially useful.
Children generally should not undergo broad carrier testing solely for future reproductive information when no immediate medical benefit exists, although testing practices vary and diagnostic questions are different. Testing is appropriate in a child with anemia, an abnormal newborn screen, or a family-specific result that affects current care.
People with beta-thalassemia disease who are planning pregnancy need specialized counseling about both inheritance and maternal health. Anemia, cardiac status, iron overload, endocrine function, medications, fertility treatment, and transfusion planning may all require attention. Carrier-screening advice alone is not enough for an affected prospective parent.
A prenatal genetic testing overview can help distinguish screening from diagnostic procedures. The final plan should come from the exact parental HBB results, not from ancestry-based risk estimates alone.
Next Steps and Pitfalls
After a carrier result, obtain the full report and arrange partner testing. The partner’s evaluation should include an appropriate CBC, iron assessment, hemoglobin analysis, and molecular testing when indicated. Testing only the same variant found in the first partner can miss a different pathogenic HBB allele.
After a two-variant or compound result, referral to a hematologist with hemoglobinopathy expertise is appropriate. Clinical classification depends on hemoglobin level, transfusion history, growth, spleen size, hemolysis, iron burden, and organ complications. A genotype that is usually mild can still require monitoring.
Common pitfalls include:
- Assuming every low MCV is iron deficiency.
- Prescribing long-term iron without documenting deficiency.
- Calling a person “negative” based only on normal hemoglobin electrophoresis.
- Failing to account for transfusion when interpreting hemoglobin fractions.
- Overlooking hemoglobin S, E, C, or another partner variant.
- Treating a VUS as proof of carrier status.
- Predicting exact disease severity from β0 or β+ labels alone.
- Forgetting that alpha-globin changes and fetal-hemoglobin modifiers can alter phenotype.
A negative HBB test with persistent microcytosis should prompt a broader review. Confirm iron status and consider alpha-thalassemia testing. If hemolysis or severe anemia is present, evaluate other red-cell disorders. The laboratory can clarify whether deletion analysis and regulatory regions were included.
Results should be revisited before a future pregnancy if the original testing was limited or if the partner changes. Carrier status itself does not change, but laboratory classification and reproductive context can. Store the exact report in a durable location and provide it to relatives or reproductive specialists when relevant.
Urgent symptoms such as marked shortness of breath, chest pain, fainting, severe pallor, rapidly worsening fatigue, jaundice, or fever in a transfusion-dependent patient require direct medical evaluation. Genetic information is important, but immediate decisions depend on the person’s current blood count, transfusion status, and organ function.
References
- Beta-Thalassemia 2024 (GeneReviews)
- 2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia 2022 (Clinical Guideline)
- Guidelines for the Management of Non-Transfusion-Dependent β-Thalassaemia 2023 (Clinical Guideline)
- Hemoglobinopathies in Pregnancy 2022 (Practice Advisory)
- Significant haemoglobinopathies: A guideline for screening and diagnosis 2023 (Clinical Guideline)
- Beta thalassemia syndromes: New insights 2025 (Review)
Disclaimer
This article provides general information and does not replace medical evaluation, hematology care, or genetic counseling. HBB results must be interpreted with blood counts, iron status, hemoglobin analysis, family history, and the partner’s findings. Do not start or continue iron treatment solely because red blood cells are small without confirming iron deficiency.
